Frank Morgan
Vice President of Investor Relations
Replay available
HCA Healthcare, Inc. (NYSE: HCA) Q4 2025 earnings conference call, held 2026-01-27. Replay captured from the company's public earnings webcast.

Vice President of Investor Relations
Chief Executive Officer
Chief Financial Officer
Analyst at UBS
Analyst at Mizuho
Analyst at Deutsche Bank
Analyst at Wolfe Research
Analyst at LeRinc Partners
Analyst at Jefferies
Analyst at RBC Capital Markets
Analyst at KeyBank
Analyst at Barclays
Analyst at Cantor Fitzgerald
Analyst at TD Cowen
Analyst at Goldman Sachs
Analyst at Stephens
Analyst at Wells Fargo
Analyst at Nephron Research
Analyst at Guggenheim
Analyst at Bank of America
Ladies and gentlemen, welcome to HCA Healthcare fourth quarter 2025 earnings conference call. Today's call is being recorded. At this time, for opening remarks and introductions, I would like to turn the call over to Vice President of Investor Relations, Mr. Frank Morgan. Please go ahead, sir. Good morning, and welcome to everyone on today's call. With me this morning is our CEO, Sam Hazen, and CFO, Mike Marks. Sam and Mike will provide some prepared remarks, and then we'll take questions. Before I turn the call over to Sam, let me remind everyone that should today's call contain any forward-looking statements, they're based on management's current expectations. Numerous risks, uncertainties, and other factors may cause actual results to differ materially from those that might be expressed today. More information on forward-looking statements and these factors are listed in today's press release and in our various SEC filings. On this morning's call, we may reference measures such as adjusted EBITDA, which is a non-GAAP financial measure. A table providing supplemental information on adjusted EBITDA and reconciling net income attributable to HCA Healthcare Inc. is included in today's release. This morning's call is being recorded and a replay of the call will be available later today. With that, I'll now turn the call over to Sam. Good morning and thank you for joining the call. We closed out the year with strong results that were mostly consistent with the previous quarters in 2025. We delivered our 19th straight quarter of volume growth, reflecting continued solid demand across our markets. The benefit of network investments and improved results in capacity management, quality patient outcomes, and stakeholder engagement. Revenue increased 6.7% compared to the prio...